- Home
- KNSA
as 10-08-2025 3:01pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $44.00 | AVG Volume (30 days): | 392.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.82 - $39.12 | Next Earning Date: | 10-28-2025 |
| Revenue: | $529,332,000 | Revenue Growth: | 56.18% |
| Revenue Growth (this year): | 37.21% | Revenue Growth (next year): | 12.07% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 29 '25 | Sell | $38.33 | 42,000 | $1,609,860.00 | 34,552 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 15 '25 | Sell | $36.73 | 16,400 | $597,975.80 | 34,552 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 5 '25 | Sell | $35.66 | 13,389 | $477,451.74 | 34,552 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 4 '25 | Sell | $35.52 | 85,271 | $3,028,825.92 | 34,552 | |
| Moat Ross | KNSA | CHIEF CORP. & COMM. OFFICER | Sep 4 '25 | Sell | $35.31 | 3,523 | $124,397.13 | 9,415 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 3 '25 | Sell | $35.50 | 15,091 | $535,730.50 | 34,552 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Sep 3 '25 | Sell | $34.84 | 11,000 | $383,240.00 | 38,011 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Aug 18 '25 | Sell | $34.11 | 16,200 | $547,141.00 | 34,552 | |
| Malley Thomas | KNSA | N/A | Aug 14 '25 | Sell | $33.09 | 78,233 | $2,588,729.97 | 12,546 | |
| Malley Thomas | KNSA | N/A | Aug 13 '25 | Sell | $33.32 | 50,129 | $1,670,298.28 | 12,546 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Zacks
a month ago
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Zacks
a month ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Zacks
a month ago
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
MT Newswires
a month ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $3,506,278, According to a Recent SEC Filing
MT Newswires
2 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $547,141, According to a Recent SEC Filing
MT Newswires
4 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,160,035, According to a Recent SEC Filing
MT Newswires
4 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $800,778, According to a Recent SEC Filing
GlobeNewswire
4 months ago
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.